238 related articles for article (PubMed ID: 33443928)
1. Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection.
Bennett J; Cunningham MT; Howard C; Hoffmann M; Plapp FV
Blood Coagul Fibrinolysis; 2021 Jun; 32(4):294-297. PubMed ID: 33443928
[TBL] [Abstract][Full Text] [Related]
2. Multimodality therapy of an acquired factor V inhibitor.
Fu YX; Kaufman R; Rudolph AE; Collum SE; Blinder MA
Am J Hematol; 1996 Apr; 51(4):315-8. PubMed ID: 8602633
[TBL] [Abstract][Full Text] [Related]
3. Acquired factor V inhibitor developing in a patient with esophageal squamous cell carcinoma.
Ahmadinejad M; Roushan N
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):97-9. PubMed ID: 23080366
[TBL] [Abstract][Full Text] [Related]
4. [Acquired factor VIII inhibitor in a patient with rheumatoid arthritis].
Ruiz-Calderón AJ; Carrasco F; Duro R; Constantino M
Sangre (Barc); 1993 Oct; 38(5):403-5. PubMed ID: 8140505
[TBL] [Abstract][Full Text] [Related]
5. [Clinical cases of acquired coagulation inhibitors].
Yamane T; Hino M; Ota K; Akahori M; Hirai M; Inoue T; Mugitani A; Tatsumi N
Rinsho Byori; 2000 Dec; 48(12):1093-101. PubMed ID: 11215417
[TBL] [Abstract][Full Text] [Related]
6. Acquired factor V inhibitor: a nation-wide study of 38 patients.
Goulenok T; Vasco C; Faille D; Ajzenberg N; De Raucourt E; Dupont A; Frere C; James C; Rabut E; Rugeri L; Schleinitz N; Sacré K; Papo T;
Br J Haematol; 2021 Mar; 192(5):892-899. PubMed ID: 33471937
[TBL] [Abstract][Full Text] [Related]
7. [Acquired inhibitor to coagulation factor V].
Takahashi I
Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):506-8. PubMed ID: 9833556
[No Abstract] [Full Text] [Related]
8. Successful treatment of a patient with idiopathic factor VIII inhibitor with double filtration plasmapheresis and steroid administration.
Yamazaki M; Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Morishita E; Nakamura S; Naito T; Ohta H
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):491-5. PubMed ID: 8329575
[TBL] [Abstract][Full Text] [Related]
9. An acquired factor V inhibitor: clinical and laboratory features.
Shastri KA; Ho C; Logue G
J Med; 1999; 30(5-6):357-66. PubMed ID: 10851568
[TBL] [Abstract][Full Text] [Related]
10. Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis.
Lemarquis A; Campbell T; Aranda-Guillén M; Hennings V; Brodin P; Kämpe O; Blennow K; Zetterberg H; Wennerås C; Eriksson K; Landegren N; Bryceson Y; Berg S; Ekwall O
J Allergy Clin Immunol; 2021 Jul; 148(1):96-98. PubMed ID: 33892926
[No Abstract] [Full Text] [Related]
11. An 89-Year-Old Man with COVID-19-Associated Coagulopathy Presenting with a Prolonged Partial Thromboplastin Time, Lupus Anticoagulant, and a High Titer of Factor VIII Inhibitor.
Ghafouri S; Rettig M; Kahlon KS
Am J Case Rep; 2020 Oct; 21():e926728. PubMed ID: 33122620
[TBL] [Abstract][Full Text] [Related]
12. High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors.
Bayani N; Rugina M; Haddad-Vergnes L; Lelong F
Am J Hematol; 2002 Sep; 71(1):33-6. PubMed ID: 12221671
[TBL] [Abstract][Full Text] [Related]
13. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.
Mühlemann B; Thibeault C; Hillus D; Helbig ET; Lippert LJ; Tober-Lau P; Schwarz T; Müller MA; ; Witzenrath M; Suttorp N; Sander LE; Drosten C; Jones TC; Corman VM; Kurth F
Clin Microbiol Infect; 2021 Oct; 27(10):1520.e7-1520.e10. PubMed ID: 34139335
[TBL] [Abstract][Full Text] [Related]
14. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases.
Spero JA
J Neurosurg; 1993 May; 78(5):817-20. PubMed ID: 8468613
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment of acquired F:VIII C inhibitor after delivery using plasmapheresis and high doses of immunoglobulins].
Belić A; Pejin D; Canak V; Felle D; Lucić A
Med Pregl; 1994; 47(9-10):359-61. PubMed ID: 7565328
[TBL] [Abstract][Full Text] [Related]
16. Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan.
Ieko M; Ohmura K; Naito S; Yoshida M; Saito M; Kiyohara K; Miyazima S; Maeta T; Ohtsu A; Shimosegawa K; Takahashi N; Ichinose A
Int J Hematol; 2022 Jan; 115(1):11-20. PubMed ID: 34476734
[TBL] [Abstract][Full Text] [Related]
17. Acquired inhibitors.
Cohen AJ; Kessler CM
Baillieres Clin Haematol; 1996 Jun; 9(2):331-54. PubMed ID: 8800509
[TBL] [Abstract][Full Text] [Related]
18. [Factor V inhibitor with double cancer].
Okajima A; Horii J; Nasu K; Niki Y; Akasaka K; Yamashita H; Sugimoto M; Yoshioka A
Rinsho Ketsueki; 1989 Apr; 30(4):514-9. PubMed ID: 2769972
[TBL] [Abstract][Full Text] [Related]
19. Acquired factor V inhibitor associated with life-threatening bleeding and a mixing test result that indicated coagulation factor deficiency.
Ashizawa M; Kimura S; Wada H; Sakamoto K; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Kako S; Yamazaki R; Oshima K; Matsuura K; Ohmori T; Madoiwa S; Nishida J; Mimuro J; Tabei K; Sakata Y; Kanda Y
Hematology; 2013 Sep; 18(5):300-4. PubMed ID: 23683688
[TBL] [Abstract][Full Text] [Related]
20. Non-specific therapy of a hemorrhagic diathesis after a bite by a young Bothrops asper (barba amarilla): a case report.
Kornalík F; Vorlová Z
Toxicon; 1990; 28(12):1497-501. PubMed ID: 2089742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
